Loading organizations...
§ Private Profile · Philadelphia, PA, USA
Proscia is a technology company.
Proscia has raised $187.0M across 8 funding rounds.
Key people at Proscia.
Proscia has raised $187.0M in total across 8 funding rounds.
Proscia provides a Concentriq enterprise digital pathology platform designed to transform pathology into a data-driven discipline. Its core offering facilitates the digitization of pathology workflows and integrates powerful AI applications to unlock new insights, accelerate discovery, and improve diagnostic precision. The platform enables pathologists and scientists to leverage advanced computing technologies within their daily routines, fostering a shift from traditional glass-slide microscopy to computational diagnostics across various specializations, including life sciences and anatomic pathology.
The company was founded in 2014 by Coleman Stavish, Nathan Buchbinder, and David West, emerging from a collaborative effort at Johns Hopkins and the University of Pittsburgh. Their initial insight stemmed from recognizing the critical need for advanced technological solutions within pathology, facing challenges such as a rising cancer burden and a shortage of specialists. The founders envisioned an open-architecture platform that could seamlessly integrate artificial intelligence, fundamentally changing how pathology is practiced to harness the potential of emerging digital data.
Proscia’s platform is utilized by a broad spectrum of diagnostic laboratories and life sciences organizations, including academic medical centers, clinical research organizations, and leading pharmaceutical companies. The long-term vision centers on continuously expanding the capabilities of digital pathology and AI to accelerate the development of new treatments and ensure more precise diagnoses. Proscia aims to empower the medical community to fully capitalize on the vast data generated in pathology, advancing the broader goal of precision medicine.
Proscia is a software company transforming pathology from analog microscope-based practices to a digital, AI-driven discipline, primarily through its Concentriq enterprise pathology platform.[1][3][6] It serves pharmaceutical companies, research organizations, academic medical centers, health systems, and diagnostic labs by enabling high-resolution image management, analysis, sharing, and AI integration to accelerate cancer research, diagnostics, and precision medicine.[1][2][6] The platform addresses core challenges like siloed data, inefficient workflows, and limited collaboration, with products like Concentriq LS for life sciences, Concentriq AP for labs, and FDA-cleared Concentriq AP-Dx for primary diagnosis—on track to support over 22,000 daily patient diagnoses in 2025 while powering novel therapies for 16 of the top 20 pharma companies.[1][3][4][6] Proscia demonstrates strong growth momentum, with revenue more than doubling in 2024 amid surging adoption, $130M in funding, and recognitions like the 2025 MedTech Breakthrough Award.[1][3][4]
Proscia was founded to modernize pathology with software, recognizing pathologists and scientists as key to advancing medicine amid outdated analog tools.[3][9] While specific founders are not detailed in available sources, the company emerged to tackle microscope-based limitations in biomedical research and diagnostics, such as inaccessible tissue images and collaboration barriers.[2][9] Early traction built through Concentriq's development as a scanner-agnostic platform integrating with major imaging hardware, lab systems, and AI, earning certifications like ISO 27001 and FDA 510(k) clearance for AP-Dx.[3][5] Pivotal moments include partnerships with global labs like the Jackson Laboratory Cancer Center (JPC) for digitizing vast tissue repositories, explosive 2024 growth with 12+ platform updates and a precision medicine AI portfolio of 120+ apps, and expansion of customer experience teams to support mission-critical deployments.[2][4]
Proscia rides the digital pathology and AI wave in precision medicine, digitizing tissue analysis to unlock data for faster drug development, trials, and diagnostics amid rising cancer burdens.[1][5][9] Timing is ideal as pathology mainstreams—AI adoption accelerates, interoperable infrastructure demand surges, and labs shift to 100% digital for efficiency and collaboration.[4][5][6] Market forces like pharma's need for real-world evidence, regulatory clearances easing clinical use, and global lab networks (e.g., 14-16 top pharmas) favor Proscia, positioning it as connective tissue reducing bottlenecks and enabling scalable growth.[1][4][5] It influences the ecosystem by fostering AI research ecosystems, partnering with CROs/hospitals, and bridging discovery-to-diagnosis, ultimately speeding therapies and improving outcomes.[2][6][9]
Proscia is primed for continued dominance as digital pathology becomes standard care, with next steps including broader AI clinical deployments, Aperture expansions for real-world evidence, and global lab network growth beyond 8M+ diagnoses.[1][4][7][9] Trends like multi-modal AI integration, regulatory tailwinds, and precision medicine demand will propel it, potentially solidifying Concentriq as the industry backbone.[5][8] Its influence may evolve from enabler to ecosystem orchestrator, rewiring pathology for unprecedented breakthroughs—reinforcing its role in turning analog data into actionable insights that save lives.[1][6]
Key people at Proscia.
Proscia has raised $187.0M in total across 8 funding rounds.
Proscia's investors include Insight Partners, Alumni Ventures, Day One Ventures, Aniq Kassam, Fusion Fund, Hummingbird Ventures, Indicator Ventures, Pareto Holdings, TSVC Capital, Valhalla Ventures, What If Ventures, Bradley Horowitz.
Proscia has raised $187.0M across 8 funding rounds. Most recently, it raised $50.0M Other Equity in March 2025.
